Takeda Pharmaceutical (NYSE:TAK) CEO Julie So-Young Kim Sells 89,090 Shares of Stock

Takeda Pharmaceutical Co. (NYSE:TAK) CEO Julie So-Young Kim sold 89,090 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $17.10, for a total transaction of $1,523,439.00. Following the completion of the sale, the chief executive officer owned 391,489 shares in the company, valued at $6,694,461.90. This represents a 18.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Stock Down 0.3%

TAK opened at $17.42 on Thursday. The company has a fifty day moving average price of $16.49 and a 200-day moving average price of $17.13. The firm has a market capitalization of $55.82 billion, a P/E ratio of 51.24 and a beta of -0.08. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.14 and a quick ratio of 0.62. Takeda Pharmaceutical Co. has a one year low of $12.99 and a one year high of $18.90.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. The firm had revenue of $6.90 billion for the quarter. Equities research analysts expect that Takeda Pharmaceutical Co. will post 3.01 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Takeda Pharmaceutical

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Valeo Financial Advisors LLC increased its holdings in shares of Takeda Pharmaceutical by 6.0% during the fourth quarter. Valeo Financial Advisors LLC now owns 11,220 shares of the company’s stock valued at $175,000 after acquiring an additional 632 shares in the last quarter. Franklin Resources Inc. grew its stake in shares of Takeda Pharmaceutical by 3.8% in the third quarter. Franklin Resources Inc. now owns 19,458 shares of the company’s stock worth $285,000 after acquiring an additional 713 shares during the period. Abel Hall LLC raised its holdings in shares of Takeda Pharmaceutical by 2.3% during the first quarter. Abel Hall LLC now owns 34,099 shares of the company’s stock valued at $632,000 after purchasing an additional 781 shares during the last quarter. Private Trust Co. NA lifted its position in Takeda Pharmaceutical by 84.7% during the fourth quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock valued at $27,000 after purchasing an additional 783 shares during the period. Finally, Checchi Capital Advisers LLC lifted its position in Takeda Pharmaceutical by 5.7% during the first quarter. Checchi Capital Advisers LLC now owns 14,591 shares of the company’s stock valued at $270,000 after purchasing an additional 786 shares during the period. Institutional investors own 9.17% of the company’s stock.

Key Takeda Pharmaceutical News

Here are the key news stories impacting Takeda Pharmaceutical this week:

• Neutral Sentiment: The sales were explicitly made to cover tax-withholding obligations tied to the vesting of equity awards, rather than representing discretionary open-market selling. Each insider retained a substantial stake after the transactions, reducing the concern that management is broadly abandoning the company. SEC insider filing
• Negative Sentiment: The volume and seniority of the sellers could weigh on investor sentiment. CEO Julie So-Young Kim sold 89,090 shares, while Andrew Stewart Plump sold 165,393 shares. General Counsel Natalie Anne Marie Furney, Giles Richard Platford, Lauren Rusckowski Duprey and several other insiders also reduced their holdings, with individual ownership declines ranging from about 6.6% to 18.5%. SEC insider filing

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Wall Street Zen upgraded Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Zacks Research upgraded Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 4th. Finally, Weiss Ratings cut shares of Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, July 30th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Takeda Pharmaceutical presently has an average rating of “Hold”.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.